AbbVie has filed a lawsuit against the Department of Health and Human Services (HHS), contesting the selection of its drug, Botox, for Medicare price negotiations. This challenge comes after the Centers for Medicare & Medicaid Services (CMS) announced 15 Medicare Part D drugs for the next round of price talks. The biopharmaceutical company is seeking to prevent Botox from being included in these negotiations.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
AbbVie sues Medicare for selecting Botox for price talks (ABBV)
AbbVie has filed a lawsuit against the Department of Health and Human Services (HHS), contesting the selection of its drug, Botox, for Medicare price negotiations. This challenge comes after the Centers for Medicare & Medicaid Services (CMS) announced 15 Medicare Part D drugs for the next round of price talks. The biopharmaceutical company is seeking to prevent Botox from being included in these negotiations.